Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Harvard University
Headquarters: Cambridge, MA, United States of America
Website: http://www.harvard.edu
Year Founded: 1636
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 14, 2025
Finance
Insilico, Lila draw nine-figure venture rounds: Finance Report
Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Oct 31, 2024
Discovery & Translation
Science Spotlight: Macrophage-fibroblast cross-talk in heart failure
BioCentury’s roundup of translational innovations also includes synthetic gene regulators, three longevity genes and more
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | Sep 19, 2024
Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | Aug 27, 2024
Emerging Company Profile
Montai: Mapping chem-bio connections to find human-vetted therapies
Flagship company uses in silico screening to mine ‘Anthromolecules’ as starting points for pills targeting well-validated pathways, with an initial focus on I&I
BioCentury | Aug 3, 2024
Deals
Biotechs find problem-solving in academia, and mostly outside the big hubs
Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Aug 1, 2024
Deals
Platform, PKU asset drive Otsuka’s $800M takeout of Jnana
As lead program nears pivotal trial, Japanese pharma adds subsidiary to build U.S. discovery capabilities; deal gives strong exit to VC syndicate
BioCentury | Jul 23, 2024
Management Tracks
Armstrong takes new role at Dana-Farber
Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentia
Items per page:
1 - 10 of 793